Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Evaluation of the impact of deltamethrin, dapagliflozin, and KB-R7943 on INa in HL-1 atrial myocytes and U2OS osteosarcoma cells: An investigative study.

Created on 21 Aug 2026

Authors

Sheng-Che Lin, Yang-Kao Wang, Sheng-Nan Wu, Edmund Cheung So

Published in

Environmental toxicology and pharmacology. Pages 105133. Aug 20, 2026. Epub Aug 20, 2026.

Abstract

The effects of deltamethrin (DLT), alone or in combination with dapagliflozin (Dapa) or KB-R7943, on INa were investigated in HL-1 cardiomyocyte and U2OS osteosarcoma cells. DLT increased both transient INa (INa(T)) and tail INa in HL-1 cells. DLT exposure enhanced the persistent INa (INa(P)) in simulated mouse or guinea-pig ventricular action potentials (APs) while co-treatment of Dapa or KB-R7943 attenuated it. DLT altered the repolarization phase of simulated mouse ventricular APs, reversing the negative-slope conductance of INa(P) to positive and was subsequently ameliorated by Dapa. In guinea-pig ventricular Aps, DLT increases INa(P) while co-treatment with KB-R7943 attenuated it. U2OS cells displayed measurable INa to brief depolarizing pulses, and was significantly enhanced by DLT. Application of either Dapa or KB-R7943 effectively reversed this DLT-induced increase in INa amplitude. Our findings show that DLT exerts a stimulatory effect on INa in both cardiac and osteoblastic cells, while Dapa and KB-R7943 counteracted it.

PMID:
42624342
Bibliographic data and abstract were imported from PubMed on 21 Aug 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 5
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement